Thirteen months ended December 31, 2021
The company reported revenue of more than $ 21 million, net income ($ 10 million), EBITDA ($ 8.2 million) and adjusted EBITDA ($ 1.7 million). Total operating expenses for the period ended December 31, 2021 were $ 6.5 million, mainly through professional fees associated with various legal and accounting activities for reverse takeovers (RTOs) and acquisitions completed during that period. The company also recorded non-cash depreciation expenses of $ 2 million relating to equipment, rights of use and intangible assets acquired during this period. Another important thing to note is the $ 1.7 million listing cost per RTO, which represents ScreenPro’s cost of getting a CSE listing. The decrease in the company’s cash flow of $ 238,288 was due to the company’s investment in the acquisition of test equipment on Covid-19 worth $ 1.6 million and laboratory equipment and equipment at $ 797,148 for further business development and profits.
“The company has created a solid and successful foundation for testing on Covid. Well-known film and production companies across Canada trust ScreenPro to ensure their safety while working during a pandemic. As the need for Covid testing grows this year, we look forward to not only accelerating our testing services but also diversifying the company to other health care products that will be as profitable as Covid testing. ” said Lena Kozovsky, CEO of the company.
“We have continued the momentum of our core business and entered 2022 with big numbers testing at Covid. We are proud of our team, which has achieved record revenue from Covid Testing, which has resulted in profits of over $ 21 million. The company is focused on agreeing with our shareholders to maximize shareholder value and continue to be opportunistic and expand our product offering in 2022, ”said Michael Jung, company chairman.
Below is selected financial information for financial results ending December 31, 2021. Please refer to the document for the 4th quarter of 2021 in full, which is available in the ScreenPro profile at www.sedar.com.
Financial results for thirteen months, financial results ended December 31, 2021:
|December 31, 2021|
|Aggregate assets||$ 4,887,202|
|The total amount of current liabilities||$ 3,969,395|
|The total amount of liabilities||$ 4,041,199|
The following table shows earnings, net losses and EBITDA * and adjusted EBITDA * for the year ended 31 December 2021 and 2020. All figures in Canadian dollars, unless otherwise indicated:
|December 31, 2021||November 30, 2020|
|Net loss||($ 10,156,501)||($ 1,040,231)|
|Depreciation and wear||$ 1,995,787||$ 45,769|
|EBITDA||($ 8,160,714)||($ 994,462)|
|Share basic compensation||–||$ 548,500|
|Excess fee for purchased net assets||$ 4,777,912||–|
|The cost of listing||$ 1,658,745||–|
|Adjusted EBITDA||($ 1,724,057)||($ 445,962)|
The company’s financial performance improved significantly in the third and fourth quarters, driven by growth due to its core business in Covid testing. Testing is still in high demand, which further improves the company’s financial position. From December 2021 to March 2022, the company conducted about 82,636 tests on Covid. In the first quarter of 2022, ScreenPro achieved a steady increase in the number of tests.
The test figures are as follows:
- In December 2021, 14,202 tests were conducted on Covid-19
- In January 2022, 19,446 tests were conducted on Covid-19
- In February 2022, 23,655 tests were conducted on Covid-19
- In March 2022, 25,333 tests were conducted on Covid-19
Due to the company’s focus on the film industry, big revenue from testing is expected in 2022 as the company does not anticipate changes in the film industry any time soon. Recently, ScreenPro announced that as of April 8, 2022, the company had received a total of 21 new productions for the first quarter of 22 Fing. As Canada faces a surge in COVID-19 cases, in 2022 the company continues to focus on the continued use of testing services as there is an increased demand for testing in the film production industry and in society.
The company continues to diversify its product and service offerings and looks forward to significant growth as it further expands into health surveys with the acquisition of Add Biomedical (“Add a biography ») and possibly other opportunities in the future. Add Bio recently applied to the Canadian Intellectual Property Office (CIPO) and the United States Patent and Trademark Office (USPTO) and plans to enter the breast cancer testing industry.
The Board of Directors has instructed ScreenPro’s management to continue to focus on revenue growth and increasing profitability in 2022 through diversification of products and services. Strategies to achieve the goals will include organic growth of subsidiaries, acquisitions, mergers or joint ventures of companies that are synergistic and have potential value for ScreenPro. The company is looking forward to an exciting 2022 year, filled with activity related to its operational and corporate goals, in particular the growth of Covid testing and expansion to other products and services for screening that will be profitable and add value to the company.
ScreenPro is a screening and medical technology company that provides turnkey survey solutions with its own software for medical alerts. ScreenPro’s unique access to several manufacturers of high-quality test kits and its strategic partnership with laboratories in British Columbia, Ontario and Quebec allows ScreenPro to be a nationwide provider of solutions for testing for COVID and breast cancer screening across Canada. In addition, ScreenPro has its own doctors and nurses with ground support staff and transportation, as well as access to high-quality PPE to ensure that customers are protected in all aspects of their testing.
For more information on ScreenPro and other corporate information, please visit the company’s website at www.screenprosecurity.com
For more information about the company, please refer to the company profile at SEDAR at www.sedar.com.
Neither the Canadian Securities Exchange (“CSE”) nor its regulatory service provider (as this term is defined in CSE policies) is responsible for the adequacy or accuracy of this release.
For more information, please contact:
Lena Kozovsky, General Director
Statements about the future:
Some of the statements contained in this news release may represent information about the future, including statements regarding expectations regarding the acquisition and business of Concierge Medical Consultants Inc. and future ScreenPro business development. Perspective information is often, but not always, defined by words such as “anticipate,” “plan,” “evaluate,” “wait,” “may,” “will,” “intention,” “should,” and similar expressions. Prospective information includes known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expected in such forward-looking information. The actual results of ScreenPro may differ significantly from those expected in this promising information as a result of regulatory decisions, competition factors in the areas in which ScreenPro operates, prevailing economic conditions, changes in ScreenPro’s strategic growth plans and other factors many of which are not controlled by ScreenPro . ScreenPro’s management believes that the expectations reflected in the forecast information in this document are reasonable, but there is no certainty that these expectations will be correct, and such promising information can not be relied upon. Any forward-looking information contained in this news release reflects ScreenPro’s expectations for the date of this and may change after that date. ScreenPro disclaims any intention or obligation to update or revise any promising information as a result of new information, future events or otherwise, except as required by applicable securities laws.
FINANCIAL ACTIONS ARE NOT IFRS
The Company has included in this press release performance indicators that do not comply with IFRS, including (a) earnings before interest, taxes, depreciation and amortization (“EBITDA”); (b) adjusted EBITDA, which is EBITDA adjusted for profit (loss) on changes in the fair value of the Company’s investment property and profit (loss) on changes in the fair value of derivative instruments; and (c) The carrying amount per share, calculated as equity held by shareholders of Datametrex AI Limited, divided by the total amount of ordinary shares outstanding at the end of the reporting period. These non-IFRS financial measurements do not have the standardized value required by International Financial Reporting Standards (IFRS) and therefore are unlikely to be comparable to similar figures provided by other issuers. Accordingly, these performance indicators are intended to provide additional information and should not be considered in isolation or as a substitute for performance measures prepared in accordance with IFRS. Management uses EBITDA to measure the profit trends of business units and segments in the consolidated group, as this eliminates the effects of financing decisions. Some investors, analysts and others use these non-IFRS financial indicators to measure the company’s financial performance. These non-IFRS financial measurements have not been presented as an alternative to net income or any other financial performance indicator required by IFRS. Reconciliation of non-IFRS non-IFRS measurements was provided within the company’s MD&A, according to the company’s profile at www.SEDAR.COM.
To view the original version of this press release, visit https://www.newsfilecorp.com/release/122456